Pipeline
Nobelpharma committed to development of critical but neglected drugs in order to fulfill social mandate
We have constantly been aspiring to conduct research and development of drugs, that are not the prime targets for many pharmaceutical companies due to questionable economic viability with a small number of patients (drugs for unmet medical needs). Our development pipeline mainly includes the drugs such as orphan drugs (drugs for rare diseases) that have been strongly requested by patients, academic societies, or the government, as well as off-label drugs and pediatric medicines. The efficient research and development processes by our small but highly capable organization is what enables us to obtain approvals for such drugs with a comparatively small market size.
While we heretofore have engaged in the development of many unapproved drugs, that were already available in US and Europe but were not developed in Japan despite their significant need, we will also actively take on the challenges of research and development under new and different concepts.
Development Process of Nobelpharma
Future Development Projects
The pipeline shows the developmental status of an unapproved drug or an unapproved indication and is not intended to promote or advertise any of the drugs.
- Note: Indicagtions and Approval are merely the expectations.
A.New Drugs, Medical Devices, and Regenerative Medical Products (including global simultaneous development products)
As of March 2026
| Compound | Expected Indication |
Partner | Phase | Expected MA | |
|---|---|---|---|---|---|
| 1 | NPC-22 Scopolamine patches |
Chronic hypersalivation | in-house | PII/III | Sep 2027 |
| 2 | NPC-33 Naxitamab |
Neuroblastoma | Y-mAbs Therapeutics, Inc. |
PI | Dec 2027 |
| 3 | NPC-30 （GAIA-102） High-activity NK-like cells |
Neuroblastoma | Gaia BioMedicine Inc. Kyushu University |
PI | Feb 2028 |
| 4 | NPC-29 Ubiquinol |
Multiple system atrophy | University of Tokyo | PIII | Aug 2029 |
| 5 | NPC-31 P092 maleate |
Prion disease | Gifu University | PI/II In preparation |
TBD |
| 6 | NPC-32 Platelet aggregation promoter |
Cardiovascular surgery, emergency and critical care area | National Defense Medical College Waseda University |
Preclinical | TBD |
| 7 | MD-02 | ENT-specific laser system | A.R.C. Laser Gmbh. | In preparation for application | TBD |
B.Life Cycle Management (LCM) (including global simultaneous development products)
As of March 2026
| Compound | Expected Indication |
Partner | Phase | Expected MA | |
|---|---|---|---|---|---|
| 1 | NPC-18 RETYMPA® |
Soft tissue defect in external auditory canal (new indication) | Kaken Pharmaceutical | In preparation for application | Mar 2027 |
| 2 | NPC-12 RAPALIMUS® |
Primary immunodeficiency syndrome (new indication) |
Institute of Science Tokyo, National Defense Medical College | In preparation for application | May 2027 |
| 3 | NPC-25 ZINTUS® |
hypozincemia (addition of new dosage form, pediatric dose) |
in-house | PIII | Sep 2027 |
| 4 | NPC-12 RAPALIMUS® |
Pure red-cell aplasia (new indication) |
Shinshu University | PIII | Jan 2028 |
| 5 | NPC-06 FOSTOIN® |
Trigeminal neuralgia (new indication) |
Pfizer Inc. | PIII | Nov 2028 |
| 6 | NPC-12 RAPALIMUS® |
Pendred syndrome (new indication) |
Keio University Kitasato University |
PII | TBD |
| 7 | NPC-12 RAPALIMUS® |
Systemic sclerosis (new indication) |
Oita University | PI/II | TBD |
| 8 | NPC-12G RAPALIMUS® Gel |
Skin lesions due to vascular abnormality (new indication) | Wakayama Medical University | PII/III In preparation | TBD |
| 9 | NPC-15 MELATOBEL® |
TBD (new indication) | in-house | PIII | TBD |
C.Overseas Development
As of March 2026
| Compound | Expected Indication |
Partner | Phase | Expected MA | ||
|---|---|---|---|---|---|---|
| 1 | NPC-02 (NOBELZIN®) |
Zinc deficiency (new indication) |
- | CH | Application pending | Dec 2026 |
| 2 | NPC-12 (RAPALIMUS®) |
Lympathic malformation | - | US | PIII | TBD |
- Research and Development